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The intracellular signaling events by which NADPH oxi-
dase-generated reactive oxygen species (ROS) modulate vas-
cular smooth muscle cell (VSMC) function and atherogenesis
are yet to be entirely elucidated.We previously demonstrated
that NADPH oxidase deficiency decreased atherosclerosis in
apoE/ mice and identified adhesion protein CD44 as an
important ROS-sensitive gene expressed in VSMC and ath-
erosclerotic lesions. Here, we examined the molecular mech-
anisms by which NADPH oxidase-generated ROS regulate
the expression of CD44 and its principal ligand, hyaluronan
(HA), and how CD44-HA interaction affects VSMC prolifer-
ation and migration and inflammatory gene expression in
apoE/ mice aortas. Thrombin-induced CD44 expression is
mediated by transcription factor AP-1 in a NADPH oxidase-
dependent manner. NADPH oxidase-mediated ROS genera-
tion enhanced thrombin-induced HA synthesis, and hyaluro-
nan synthase 2 expression in VSMC. Hyaluronidase, which
generates low molecular weight HA (LMW-HA), is induced
in VSMC in a NADPH oxidase-dependent manner and
LMW-HA stimulated ROS generation and cell proliferation
in wild-type but not p47phox/ VSMC, effects that were
enhanced by thrombin pretreatment. Haptotactic VSMC
migration toward HA was increased by thrombin in a CD44-
dependent manner. HA expression in atherosclerotic lesions
and plasma-soluble CD44 and HA levels were higher in
apoE/ compared with apoE//p47phox/ mice. HA-reg-
ulated pro-inflammatory gene expression was higher in
apoE/ than apoE//p47phox/ mouse aortas. GKT136901,
a specific inhibitor of Nox1- and Nox4-containing NADPH
oxidase activity, attenuated ROS generation and atheroscle-
rosis and decreased CD44 and HA expression in atheroscle-
rotic lesions. Together, these data suggest that increased
CD44 andHA expression and CD44-HA-dependent gene reg-
ulation may play a role in atherosclerosis stimulated by
NADPH oxidase activation.
Atherosclerosis is a chronic inflammatory disease of the ves-
sel wall in which reactive oxygen species (ROS)3-mediated acti-
vation of redox-sensitive transcription pathways modulates
atherosclerotic plaque progression. Increased adhesion mole-
cule expression and remodeling of extracellular matrix are
among the major changes caused by the activation of redox-
sensitive signaling pathways. NADPH oxidases are critical
determinants of the redox status of the vessel wall and play a
critical role in the pathophysiology of atherosclerosis.
Several homologs of the gp91phox (Nox2) catalytic moiety of
multisubunit NADPH oxidase (Nox): Nox1, Nox3, Nox4,
Nox5, Duox1 and Duox2, have been recently identified (1). All
Nox homologs are transmembrane proteins that possess six
transmembrane domains with conserved binding sites for FAD
and NADPH and four heme-binding histidines in the third and
fifth transmembrane domains. The Nox moieties have distinct
subcellular localizations (2) and are differentially regulated. For
the Nox2-containing NADPH oxidase, catalytic activity is ini-
tiated following assembly of cytosolic subunits p47phox and
p67phox with the membrane-bound Nox2, a process that
requires phosphorylation of p47phox and p67phox, protein-pro-
tein interaction, and binding of G protein Rac (1). In the case of
Nox1 andNox3-basedNADPHoxidases, the cytosolic subunits
p47phox and p67phox are replaced by Nox organizer 1 and Nox
activator 1, respectively. The activation of Nox4 does not
require any of the cytosolic subunits mentioned above. How-
ever, Lyle et al. (3) recently reported that polymerase -inter-
acting protein 2 associates with p22phox to activate Nox4-based
NADPH oxidase. Nox1- and Nox4-based enzymes are the pre-
dominant NADPH oxidases in mouse vascular smooth muscle
cells (VSMC).
CD44 is a major cell surface adhesionmolecule expressed on
many vascular cell types including leukocytes, macrophages,
endothelial cells, and VSMC. The expression of CD44 is regu-
lated in a NADPH oxidase-dependent manner (4). In its extra-
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cellular domain, CD44 contains hyaluronan-binding site
through which it anchors hyaluronic acid (HA) to the cell sur-
face. The binding of HA to CD44 has been shown to regulate
cell activation, proliferation, migration, signal transduction,
and gene expression (5).
Consistent with its pleiotropic function, altered expression
or dysfunction ofCD44has beenproposed to be contributory in
several pathological conditions. CD44 expression is up-regu-
lated in mouse and human atherosclerotic lesions (4, 6–8) and
in neointimal VSMC after arterial injury (4, 9). CD44-deficient
apoE/ mice develop markedly decreased atherosclerosis as
compared with wild-type apoE/ littermates (6). Proteolytic
cleavage of the CD44 extracellular domain from the cell surface
by metalloproteases generates soluble CD44, and circulating
soluble CD44 levels are increased in humans with various
inflammatory diseases and malignancies (10, 11). To date, a
direct association between circulating soluble CD44 levels and
human atherosclerosis has not been clearly established (12).
HA, a major glycosaminoglycan constituent of the extracel-
lular matrix, is the principal ligand of CD44. HA also binds to
other cell surface receptors such as RHAMM (receptor for HA-
mediated motility) and LYVE-1 (lymphatic vessel endothelial
HA receptor). HA polymers range in sizes and have wide rang-
ing and sometimes opposing biological function depending on
the size (13). Interaction ofHAwith cell surface receptors and a
variety of hyaladherins such as link protein, versican, and tumor
necrosis factor-induced gene-6 can result in the formation of
extracellular matrix that makes up the microenvironment of
VSMC (14).
HA is synthesized on the cytoplasmic surface of the plasma
membrane by integral glycosyl transferases and is exported
directly into the extracellular space (15). There are three dis-
tinct HA synthase genes (Has1, Has2, and Has3) in mammals.
HAS2 is the major HAS isoform in VSMC (16). Constant HA
turnover occurs under normal physiologic conditions and the
increase in HA levels during pathophysiologic conditions
reflects the balance between its synthesis and catabolism. Hya-
luronidase is the enzyme that degrades HA and two distinct
hyaluronidase genes (Hyal1 and Hyal2) have been reported to
be involved in the intracellular and extracellular catabolism of
HA in a CD44-dependent manner (17). In addition, ROS can
degrade HA under oxidative conditions (18).
Because of its interaction with cell surface receptors, HA
affects cell behavior through direct receptor-mediated effects
on gene expression (19). Alterations in HA metabolism, distri-
bution, and function have been documented in many diseases
(14). HA was shown to regulate VSMC proliferation and acti-
vation in vitro (6) and overexpression of HA in aortic VSMC of
apoE/ mice has been shown to promote atherosclerosis
development (20). Increased HA levels have been observed in
injured rat carotid arteries and human restenotic arteries and
atherosclerotic lesions (21, 22). Increased HA synthesis by
saphenous vein VSMC is thought to contribute to saphenous
vein graft failure in bypass patients (23) and selective accumu-
lation of HA is associated with the proliferation and migration
of VSMC and thrombosis of eroded plaques (22).
In the present study, we investigated the role of NADPH
oxidases in thrombin-induced regulation of CD44 and HA
expression in mouse VSMC and atherosclerosis. Our results
demonstrate that NADPH oxidase plays a critical role in the
regulation of both CD44 and HA expression in VSMC treated
with thrombin. Low molecular weight HA (LMW-HA)
enhances thrombin-induced NADPH oxidase activity and pro-
liferation of VSMC, and HA-induced VSMC proliferation is
regulated in a CD44-dependent manner. Absence of NADPH
oxidase results in decreased levels of HA in the atherosclerotic
lesions and soluble CD44 in the plasma and inflammatory gene
expression in the aortic wall of apoE/mice. Additionally, our
data suggest that Nox1- and Nox4-based NADPH oxidase
inhibitors attenuate CD44 and HA expression in human aortic
SMC and apoE/ mice and decrease oxidative stress and ath-
erosclerosis in the aortas of apoE/ mice.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents—If not stated otherwise, all chemi-
cals were obtained from Sigma. 2,3-Dimethoxy-1,4-naphtho-
quinone (DMNQ)was purchased fromCalbiochem. LMW-HA
fragments were generated by sonication (24). Human-throm-
binwas purchased fromHematologicTechnologies, Inc. Rabbit
anti-CD44 antibody and goat anti-HAS2 antibody were pur-
chased from Santa Cruz Biotechnology. Mouse anti--actin
antibody was obtained from Sigma. [3H]Thymidine and UDP-
[14C]glucuronic acid were from PerkinElmer Life Sciences.
GKT136901 (2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-
yl-methyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione),
a small molecule dual Nox1/Nox4 inhibitor (25) was provided
by GenKyoTex S.A, and prepared in 0.5% carboxymethylcellu-
lose, 0.25% Tween 20, 1% dimethyl sulfoxide. Luciferase reporter
construct containing the human CD44 promoter fragment with
regular ormutatedAP-1 binding sitewere generously provided by
Dr. Ashok Kumar, University of Ottawa (26).
Cell Culture—VSMC were isolated from aortas of 4-month-
old wild-type, p47phox/ and CD44/ C57BL/6 mice as pre-
viously described (27). Aortas were dissected and digested with
collagenase to remove adventitia and endothelium and then
digested with collagenase and elastase at 37 °C for 1 h. VSMC
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% (v/v) fetal bovine serum (FBS) as previously
described (28). Human aortic smooth muscle cells (HASMC)
were purchased from Invitrogen and grown in smooth muscle
basal medium supplemented with growth factors (SmGM-2,
Lonza). All experiments were conducted using VSMC between
passages 4 and 11 that were growth arrested by incubation in
DMEM containing 0.1% FBS for 72 h.
Mice and Diet—Wild-type, p47phox/, CD44/, apoE/,
and apoE//p47phox/ mice were bred in-house as previ-
ously described (29). All mice were on C57BL/6 genetic back-
ground. p47phox/ and CD44/ mice were backcrossed for
10 generations. Animals were maintained at 22 °C with a 12-h
light/dark cycle and were fed standard rodent chow until 7–8
weeks of age and then a Western diet (42% fat, Harlan Teklad/
TD88137) for 12 more weeks. GKT136901, at a concentration
of 10 mg/kg of body weight, was delivered through oral gavage
using 20-gauge gavage needles once daily and 5 days a week for
12 weeks. All procedures involving the experimental animals
were performed in compliance with protocols approved by
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University of North Carolina IACUC according to NIH
guidelines.
AP-1 Transcription Factor Activity—Nuclear extracts from
thrombin- and vehicle-treated VSMC were prepared with the
NucBuster Protein Extraction Kit (Novagen) according to the
manufacturer’s protocol. AP-1 DNA binding activity was mea-
sured using the TransBinding AP-1 Assay Kit (Panomics).
Briefly, nuclear extracts were incubated with biotinylated
AP-1-consensus binding sequence oligonucleotides and the
complexes bound to the oligonucleotides were detected using a
primaryAP-1 antibody and a secondary antibody conjugated to
horseradish peroxidase. AP-1 activity was assayed by mea-
suring the absorbance at 450 nm.
Nuclear Run-on Assay—Nuclei from thrombin-, DMNQ-,
and vehicle-treatedVSMCwere isolated by lysing cells in 250l
of lysis buffer (10mMNaCl, 3mMMgCl2, 10mMTris-HCl, 0.5%
Nonidet P-40, pH 7.4) and then resuspended in nuclei storage
buffer (40% glycerol, 50 mM Tris-HCl, 5 mM MgCl2, 0.1 mM
EDTA, pH 8.5). Run-on transcription was done at room tem-
perature for 30 min in a 100-l volume with 2 reaction mix-
ture containing 4 reaction buffer (100 mM HEPES, 10 mM
MgCl2, 10 mM DTT, 300 mM KCl, 20% glycerol), 1 mM NTPs,
and 250 Ci of [-32P]UTP. Reactions were stopped by the
addition of 2 units of DNase I at 37 °C for 10 min followed by
incubation with 300 l of stop buffer (2% SDS, 7 M urea, 0.35 M
NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0) and 15 l of pro-
teinaseK (Qiagen) at 45 °C for 2 h.Dot blots containing 10g of
denaturated CD44 and 18 S cDNAs were hybridized with
nuclear run-on products in 5 ml of QuikHyb Hybridization
Solution (Stratagene) at 42 °C for 24 h. The membranes were
washed twice for 15 min at room temperature with 2 SSC,
0.1%SDS and then once for 30min at 60 °Cwith 0.1 SSC, 0.1%
SDS. Blots were analyzed by autoradiography.
RNA Extraction and Real Time RT-PCR—Total RNA from
untreated and thrombin-treated wild-type and p47phox/
cells was extracted using the RNeasy Micro Kit (Qiagen).
RNA from mouse aortas was extracted with the MELTTM
Total Nucleic Acid Isolation System (Ambion). Reverse
transcription was performed with 1 g of total RNA using a
TaqMan Reverse Transcription Reagent kit (Applied
Biosystems). TaqMan Gene Expression Assays for mouse
Cd44 (Mm01277161_m1), Has2 (Mm00515089_m1), Hyal3
(Mm00662097_m1), Ccl2 (Mm00441242_m1), Ccl4
(Mm00443111_m1), Ccl5 (Mm01302428_m1), Tnf
(Mm00443258_m1), Il1 (Mm00434228_m1), Igf1
(Mm00439560_m1) and for human Cd44 (Hs01075861_m1),
Has2 (Hs00193435_m1), Nox1 (Hs00246589_m1), and Nox4
(Hs00418356_m1) were purchased from Applied Biosystems.
Real time RT-PCR was carried out using the ABI PRISM 7900
HT Sequence Detection System and TaqMan PCRMaster Mix
according to the manufacturer’s recommendations. Sequence
Detection System software (Applied Biosystems) was used for
raw data processing and analysis. The data for each gene were
analyzed by REST2005 (Relative Expression Software Tool)
(30). Relative expression of each gene was determined by nor-
malization to 18 S ribosomal RNA expression.
Transient Transfection and Luciferase Activity Assay—
VSMC were transfected with CD44 promoter luciferase
reporter or pCMV--galactosidase constructs using theGenJet
In Vitro DNA Transfection Kit for SMC (SignaGen Laborato-
ries) as recommended by manufacturer. Cell suspensions were
incubated for 20 min at 37 °C with 1 g of CD44 promoter
constructs and 0.5 g of pCMV--galactosidase constructs
mixed with 6 l of GenJet reagent and serum-free DMEM.
Fresh 10% FBS/DMEMwas added to themixture and cells were
plated on 12-well plates. After 24 h, cells were quiesced in 0.1%
FBS/DMEM for 72 h. Cells were treated with thrombin or vehi-
cle for 8 h and lysed in GloLysis buffer (Promega). Cell lysate
was mixed with either Bright-Glo luciferase substrate or Beta-
Glo galactosidase substrate (Promega) in equal amounts. After
a 10-min incubation, luminescencewasmeasured usingWallac
1420 Multilabel plate reader.
Measurement of CD44mRNAStability—VSMCwere treated
with thrombin or vehicle for 4 h prior to the addition of actino-
mycin D (5 g/ml). RNA was extracted at 0, 2, 4, and 6 h and
analyzed with real time RT-PCR as described above.
Rac1 Activation Assay—Cell lysates from thrombin- and
LMW-HA-treated VSMC were analyzed for Rac1 activation
using the PAK-1 PBD pull-down method (Rac1 Activation
Assay Kit, Millipore). This assay uses the Rac downstream
effector, p21-activated protein kinase (PAK), to isolate the
active GTP-bound form of Rac from the sample. The p21 bind-
ing domain (PBD) of PAK-1 is expressed as a GST fusion pro-
tein and coupled to agarose beads. Cell lysates were precleared
with 100 l of glutathione-agarose and then immunoprecipi-
tated with 10 g of PAK-1 PBD at 4 °C overnight. Agarose
beads were washed and analyzed byWestern blot using mouse
anti-Rac1 antibody. Nonimmunoprecipitated lysates were ana-
lyzed by Western blot to adjust for protein loading.
Western Analysis—Western analysis was performed as de-
scribed previously (28).
Intracellular ROS Detection—VSMC grown in glass-bottom
plates were washed with Hanks’ buffered salt solution and
loaded with 10 M H2DCFDA (Invitrogen) in Hanks’ buffered
salt solution at 37 °C for 30 min and stimulated with Hanks’
buffered salt solution containing 10 M H2DCFDA and either
thrombin or LMW-HA. Fluorescence was read at 535 nmusing
Wallac 1420 Multilabel plate reader. VSMC treated with
thrombin or LMW-HA were incubated with 10 M dihydro-
ethidium (DHE, Invitrogen) at 37 °C for 30 min. DHE fluores-
cence was obtained at 590 nm in several visual fields using a
Leica DMIRB fluorescent microscope.
In Vitro Hyaluronan Synthase Activity Assay—VSMC were
treated with thrombin or vehicle for 6 h and hyaluronan syn-
thase (HAS) activity assay was performed as described previ-
ously (31). Cells were washed, incubated in lysis buffer (10 mM
KCl, 1.5 mM MgCl2, 10 mM Tris-HCl, pH 7.4) for 10 min,
scraped, and homogenized using a Dounce homogenizer.
Nuclei were removed by centrifuging at 1,000  g for 4 min.
Membrane fragments were separated by centrifugation at
16,000  g for 25 min and resuspended in 100 l of lysis buffer
supplementedwith protease inhibitors. HAS activity was deter-
mined in 100 l of 25 mM HEPES (pH 7.1) containing 15 mM
MgCl2, 5 mM dithiothreitol, 0.2 g of aprotinin, 5 g of leupep-
tin, 1 mM UDP-GlcNAc, 50 M UDP-GlcA, 0.25 Ci of UDP-
[14C]glucuronic acid, and 50 g of cell membranes. The reac-
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tion mixture was incubated at 37 °C for 1 h and terminated by
boiling. The reaction mixtures were divided in two and treated
with or without Streptomyces hyaluronate lyase at 37 °C
overnight and then with 200 mg/ml of Pronase for 5 h. Depro-
teinized samples were centrifuged in Amicon Ultracell-100
Centrifugal Filters (Millipore) to remove unincorporated
[14C]glucuronic acid. Recovered samples were analyzed by liq-
uid scintillation counting. HAS activity was calculated based on
the incorporation rate of labeled glucuronic acid and as a frac-
tion of HA removed by hyaluronate lyase treatment.
Histology and Immunostaining—Themouse heartswere per-
fused with PBS, embedded in OCT compound (Tissue-Tek),
and snap-frozen in liquid nitrogen. Transverse serial sections
were collected from the proximal aorta up to 560 m of the
cardiac tissue. Representative sections were stainedwith oil red
O. Frozen sections were fixed in acetone and blocked with 0.3%
H2O2 inmethanol. Sections were immunostainedwith rat anti-
mouse CD44 and CD11b antibodies (BD Pharmingen) or bio-
tinylated HA-binding protein (Calbiochem) using the Vec-
tastain Elite ABC Kit and Vector DAB Substrate Kit (Vector
Laboratories). EPOSTM Anti-human Smooth Muscle Actin/
HRP antibody (DakoCytomation) was used with Vector DAB
Substrate Kit (Vector Laboratories). VSMC were grown on
chamber glass slides, treated with thrombin and hyaluronidase
from Streptomyces hyaluronlyticus (Calbiochem). Cells were
fixed inmethanol at20 °C for 10min and in acetone at20 °C
for 1 min. Staining for HA was carried out using biotinylated
HA-binding protein (HABP) with Vectastain Elite ABCKit and
Vector DAB Substrate Kit (Vector Laboratories). The numeric
immunohistochemistry scoring (1, weak; 2, moderate; and 3,
strong staining intensity) was performed by two independent
observers blinded to the sample identity.
Haptotactic Cell Migration Assay—Cell migration assays
were performed using 8-m pore size Transwell chambers
(Corning). The bottom side of the filters was coated with 100
g/ml of HMW-HA or BSA. The filters were washed and
blocked with 2% BSA in PBS. VSMC treated with vehicle or
thrombin for 8 h were trypsinized, centrifuged, and resus-
pended in DMEM. Cells were incubated with 2 units/ml of
thrombin, rat anti-mouse CD44 monoclonal antibody (Milli-
pore), or normal mouse IgG (Santa Cruz Biotechnology) at
37 °C for 30 min, and 2  104 cells were seeded on the top of
Transwell filters. Cells were incubated at 37 °C for 16 h. Tran-
swells were washedwith PBS, cells from the top side of the filter
were removed with a cotton swab, and cells on the bottom side
of the filter were stained with hematoxylin (Vector Laborato-
ries). The number of stained cells in 10  10-mm grid was
scored for six random fields (20 objective) per Transwell fil-
ter. The average number of cells that migrated per filter was
calculated.
[3H]Thymidine Incorporation Assay—VSMC were plated at
equal densities (2.5 104), quiesced, and either pretreatedwith
thrombin for 8 h and then treated with LMW-HA for 24 h or
treatedwith thrombin or LMW-HA for 24 h alone. [3H]Thymi-
dine (1 Ci/ml) was added for the last 4 h of treatment. Cells
were then washed, treated with cold 5% trichloroacetic acid at
4 °C for 30 min, and lysed in 1 M sodium hydroxide. [3H]Thy-
midine incorporation was determined by liquid scintillation
counting.
Plasma Sample Collection and Hyaluronic Acid, Soluble
CD44, and 8-Isoprostane ELISA—Blood sampleswere collected
from deeply anesthetized mice through cardiac puncture and
centrifuged at 1000  g for 10 min for separation of plasma.
Samples were stored at 80 °C until assayed. The concentra-
tion of HA in mouse plasma was measured using HA-ELISA
(Echelon Biosciences) as described by the manufacturer. The
Human CD44 ELISA kit (Cell Sciences) was used to measure
soluble CD44 in mouse plasma and CD44 in protein lysates
frommouse aortas. Plasma concentration of free 8-isoprostane
wasmeasured using the 8-isoprostane EIAKit (CaymanChem-
ical) according to the manufacturer’s protocol.
Statistical Analysis—Datawere analyzed by one-way analysis
of variance and post hoc analysis was performed using New-
man-Keuls test. Student’s t test was used to compare athero-
sclerosis, DHE fluorescence, 8-isoprostane levels, and immu-
nohistochemistry scoring in mice treated with vehicle or
GKT136901. Gene expression results in VSMC were analyzed
by two-way analysis of variance followed by Bonferroni post-
test. Differences were considered significant at p  0.05.
RESULTS
Thrombin Induces Cd44 Expression in VSMC through
NADPH Oxidase-dependent Activation of AP-1—We previ-
ously reportedNADPHoxidase-dependent regulation of CD44
expression in wild-type VSMC treated with thrombin for 8 h
(4). Consistentwith these findings, a time-dependent activation
ofCd44mRNA expression was observed in response to throm-
bin treatment inwild-typeVSMC, but not in p47phox/VSMC
(Fig. 1A). To determine whether differences in Cd44 mRNA
levels between wild-type and p47phox/ VSMC were due to
differences in gene transcription or mRNA stability, we first
measured de novo transcription in nuclear run-on experiments.
Thrombin treatment for 3 h resulted in a 2-fold increase in
transcription of Cd44 RNA (p  0.05) in wild-type VSMC but
had no significant effect in p47phox/ cells (Fig. 1B). The
thrombin-induced increase in CD44 mRNA expression was
effectively blocked by pretreatment with diphenyleneiodonium
chloride, an inhibitor of NADPH oxidases and other flavin-
containing enzymes. Further support for redox-dependent reg-
ulation of Cd44 mRNA expression was evident in wild-type
VSMC treated with DMNQ, a redox cycling quinone known to
induce ROS generation in VSMC (32).
Because the transcription factor AP-1 has been demon-
strated to regulate CD44 expression during an inflammatory
response in VSMC (33) and ROS have been implicated in the
activation of AP-1 (34), we investigated activation of AP-1 in
VSMC after treatment with thrombin. AP-1 DNA binding
activity increased significantly (80%, p  0.05) at 2 h and
remained elevated for up to 4 h after thrombin treatment in
wild-type but not in p47phox/ cells (Fig. 1C). To determine
whether NADPH oxidase-dependent increased AP-1 DNA
binding activity is the mechanism for increased CD44 expres-
sion, wild-type and p47phox/ VSMC were co-transfected
with Cd44 promoter-luciferase reporter gene constructs con-
taining either an AP-1 binding sequence (from 5 334 to 3
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53 bp containing gctgcttagtca) or a mutant AP-1 binding
sequence (334 mAP-1 containing gctgcctaggca) (26). The
transfected cells were then treated with thrombin. Luciferase
activities were 6.7-fold higher in thrombin-treated wild-type
VSMC compared with untreated cells (Fig. 1D).Wild-type cells
transfected with the mutant AP-1 CD44 promoter-luciferase
reporter gene construct showed almost complete inhibition of
luciferase activity in response to thrombin treatment compared
with wild-type cells transfected with the control AP-1 CD44
promoter-luciferase reporter gene construct. Importantly,
transfection of p47phox/ VSMC with either control or the
mutant AP-1 CD44 promoter-luciferase reporter gene con-
struct failed to show any significant
increase in luciferase activity com-
pared with their respective controls
(Fig. 1D).
We next investigated whether
thrombin enhances the expression
of CD44 by altering the stability of
Cd44 mRNA. The half-life of Cd44
mRNA in control and thrombin-
treated wild-type VSMC was as-
sessed bymRNA chase experiments
using the transcription inhibitor
actinomycin D. CdD44 mRNA sta-
bility was not altered by thrombin
(Fig. 1E). Together, these results
indicate that thrombin-induced
CD44 expression in VSMC is regu-
lated by AP-1 in NADPH oxidase-
dependent manner.
Thrombin-induced HA Synthesis
and Degradation in VSMC Are Reg-
ulated by NADPH Oxidase—A
number of proatherogenic effects
elicited by CD44 in vascular cells,
includingVSMCdifferentiation and
activation (6), production of soluble
inflammatory markers such as
interleukin-12 (35), MCP-1 (36),
iNOS (37), are largely mediated
through the interaction of CD44
with HA (LMW-HA in particular).
To determine whether activation of
NADPH oxidase by thrombin has
an effect on HA synthesis, we per-
formed immunocytochemical anal-
ysis of wild-type and p47phox/
VSMC treated with thrombin using
HABP (Fig. 2A). Thrombin markedly
increased HA synthesis in wild-type
cells compared with p47phox/ cells.
Hyaluronidase treatment prior to
immunostaining, to catabolize extra-
cellularHAand thus demonstrate the
specificity of HABP in recognizing
HA, abrogated HA staining of both
the cell types.
Hyaluronan synthase 2 (HAS2) is a major source of HA (38,
39). Quantitative RT-PCR analysis was used to determine
whether the observed thrombin-induced increase in HA levels
in wild-type VSMC resulted from increased synthesis. A time-
dependent increase in Has2 expression was observed in wild-
type VSMC treated with thrombin (Fig. 2B). A 3.6-fold increase
(p 0.01) inHas2 expression was observed in wild-type VSMC
at 4 h after thrombin stimulation. Consistent with the putative
role ofNADPHoxidase in regulatingHA levels, thrombin treat-
ment had no significant effect on Has2 expression in
p47phox/ VSMC. Thrombin also had no significant effect on
Has1 and Has3 expression in either cell type (data not shown).
FIGURE 1. NADPH oxidase-dependent activation of AP-1 regulates thrombin-induced Cd44 gene expres-
sion. A, real time RT-PCR analysis of Cd44 expression in wild-type and p47phox/ VSMC treated with thrombin.
Data are expressed as fold-change in gene expression relative to untreated controls (mean  S.E., n  3, *, p 
0.01; **, p  0.001). B, nuclear run-on analysis of Cd44 transcription. Wild-type VSMC were pretreated with 20
M diphenyleneiodonium chloride (DPI) for 30 min before treatment with 1 unit/ml of thrombin or 1 M DMNQ
for 3 h. p47phox/ cells were treated with or without thrombin and nuclear extracts were analyzed by dot-blot.
Densitometric analysis of Cd44 mRNA expression, represented as fold-change, was calculated by first normal-
izing to 18 S RNA levels in individual samples and then relative to untreated wild-type control (mean  S.E., n 
3, *, p  0.05). C, DNA binding activity of AP-1 was assayed in wild-type and p47phox/ VSMC after thrombin
treatment. Data were expressed as absorbance at 450 nm (mean  S.E., n  3, *, p  0.05, two-way analysis of
variance). D, AP-1-dependent Cd44 promoter activity was assayed in wild-type and p47phox/ cells treated
with thrombin. Cells were transiently co-transfected with Cd44 promoter-luciferase constructs containing
normal (334) or mutated AP-1 (334 mAP-1) binding sequences and -galactosidase control plasmid. After
48 h, cells were treated with vehicle or thrombin for 6 h followed by luciferase and -galactosidase activity
measurement. Data represent fold-change in luciferase activity, normalized to -galactosidase activity, in
thrombin-treated cells compared with their respective controls (mean  S.E., n  3, *, p  0.05). E, effect
of thrombin on Cd44 mRNA levels in the presence of actinomycin D. VSMC were pretreated with either
vehicle or thrombin for 4 h and then treated with actinomycin D for the indicated times. Cd44 RNA levels,
assessed using real-time RT-PCR, were normalized to 18 S RNA levels. Data represent the fold-change in
mRNA level relative to time 0 of actinomycin D addition (mean  S.E., n  3).
NADPH Oxidases Regulate CD44 and Hyaluronic Acid Expression
AUGUST 20, 2010 • VOLUME 285 • NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26549
Thrombin-induced increase inHas2mRNA levelswas followed
by a significant increase in the expression of HAS2 protein lev-
els at 6 and 8 h in wild-type cells, but not in p47phox/ cells
(Fig. 2C). We then examined whether thrombin also regulates
HAS activity in NADPH oxidase-dependent manner (Fig. 2D).
Thrombin increased HAS activity by 40% in wild-type VSMC
after 6 h treatment (p  0.05), whereas it had no significant
effect on the activity of this enzyme in p47phox/ cells (Fig.
2D). Interestingly, thrombin treatment also caused a time-de-
pendent increase in the expression of hyaluronidase 3 (Hyal3)
in wild-type, but not in p47phox/ VSMC (Fig. 2E). Hyal3
mRNA expression was 4.4-fold higher (p  0.01) in wild-type
VSMC than in p47phox/ VSMC at 8 h after thrombin treat-
ment. Thrombin had no significant effect on Hyal1 and Hyal2
expression in either cell type (data
not shown). Taken together these
data suggest that NADPH oxidase
activation mediates thrombin-in-
ducedHA levels inVSMCby regulat-
ing both synthetic and degradation
enzymes. Furthermore, ROS-regu-
lated expression of Hyal3 may lead
to enhanced degradation of HA and
generation of biologically active
LMW-HA.
Interaction of Thrombin with
LMW-HAInducesROSGeneration in
NADPH Oxidase-dependent Manner
via the Activation of Rac1—A sus-
tained and marked increase in
thrombin concentration occurs
after arterial injury (40) and active
thrombin has been shown to be
present in human atherosclerotic
lesions (41). Accumulation of HA
has been observed in the plaque/
thrombus interface in humans (22).
Because these events likely involve
NADPH oxidase activation, we
investigated whether thrombin and
LMW-HA interaction increases
oxidative stress in VSMC. First, we
quantified ROS production by mea-
suring DCF fluorescence. Thrombin
caused a 50% increase (p  0.05) in
DCF fluorescence in wild-type
VSMC, but no significant increase
in p47phox/ VSMC (Fig. 3A).
LMW-HA treatment significantly
increasedDCF fluorescence inwild-
type (p  0.05) but not in
p47phox/ cells. Wild-type VSMC
pretreated with thrombin for 8 h
and then treated with LMW-HA
had 90% higher fluorescence com-
pared with control cells (p  0.001)
and 30% higher fluorescence than
thrombin-treated cells (p  0.05)
(Fig. 3A). Thrombin pretreatment followed by LMW-HA treat-
ment had no significant effect on DCF fluorescence in
p47phox/ cells. Similar to its effect in wild-type cells, throm-
bin increased DCF fluorescence by 50% (p  0.05) in CD44/
VSMC (Fig. 3A). However, LMW-HA alone or pretreatment
with thrombin followed by LMW-HA treatment had no signif-
icant effect on DCF fluorescence in CD44/ VSMC, indicat-
ing that interaction of thrombin-inducedCD44with LMW-HA
induces ROS generation in VSMC.
To confirm these results, we analyzed DHE fluorescence in
wild-type, p47phox/, and CD44/ VSMC treated with
thrombin, LMW-HA, or both. Amarked increase in DHE fluo-
rescence was observed in wild-type and CD44/ VSMC
treatedwith thrombin (data not shown). DHE fluorescence was
FIGURE 2. NADPH oxidase regulates thrombin-induced increases in HAS2 and Hyal3 expression and HAS
activity in VSMC. A, VSMC were treated with thrombin for 24 h. HA was detected using biotinylated HABP.
Pericellular localization of HA was shown by treatment with hyaluronidase for 30 min before staining with
HABP. B, real time RT-PCR analysis of Has2 RNA expression in VSMC treated with thrombin for the indicated
times. Data represent fold-change in gene expression, normalized to 18 S RNA, and relative to untreated
wild-type control (mean  S.E., n  3, *, p  0.001). C, Western blot analysis of HAS2 protein levels in VSMC
treated with thrombin. Densitometric analysis of protein levels, represented as fold-change, was calculated by
first normalizing to -actin levels in individual samples and then relative to untreated wild-type control
(mean  S.E., n  3, *, p  0.05). D, total HAS activity was measured in wild-type and p47phox/ VSMC treated
with thrombin or vehicle by analyzing UDP-[14C]glucuronic acid incorporation rate. Data expressed as enzyme
activity in picomole/h adjusted for total protein concentration (mean  S.E., n  4, *, p  0.05, NS, not signif-
icant). E, real time RT-PCR analysis of Hyal3 expression in VSMC treated with thrombin. Data expressed as
fold-change in gene expression normalized to 18 S RNA and relative to untreated wild-type control (mean 
S.E., n  3, *, p  0.05).
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further enhanced in wild-type cells pretreated with thrombin
for 8 h followed by treatment with LMW-HA, but not in
CD44/ VSMC. In contrast, none of these treatments signif-
icantly affected DHE fluorescence in p47phox/ cells (data not
shown).
Because both thrombin and HA are known to activate Rac1
GTPase (42, 43), a regulatory subunit of NADPH oxidase, we
investigated the interaction of thrombin and LMW-HA on
Rac1 activity by performing a PAK-1 PBD pulldown assay.
Thrombin and LMW-HA increased Rac1 activity in wild-type
cells by 80 and 70%, respectively (p  0.05). Pretreatment with
thrombin for 8 h prior to LMW-HA treatment increased Rac1
activity by 130% relative to untreated control (p 0.001) and by
35% relative to LMW-HA treatment alone (p  0.05) (Fig. 3B).
Thrombin significantly increased Rac1 activity in CD44/
VSMC (p  0.05) (Fig. 3B), but LMW-HA or thrombin pre-
treatment followed by LMW-HA had no significant effect on
Rac1 activity in CD44/ VSMC. Thrombin, LMW-HA, or
thrombin pretreatment followed by LMW-HA had no signifi-
cant effect on the activation of Rac1 GTPase in p47phox/
VSMC. Combined with our previous observations (4), these
data suggest that NADPH oxidase is necessary for thrombin-
induced CD44 expression and interaction of CD44 and HA,
which in turn, activate NADPH oxidase.
LMW-HA Augments Thrombin-induced Proliferation of
VSMC and CD44 Regulates Thrombin-induced Haptotactic
Migration of VSMC toward HMW-HA—LMW-HA regulates
VSMC proliferation in a CD44-dependent manner (6). To
determine the role of ROS and confirm that of CD44 in LMW-
HA-inducedVSMCphenotype, wemeasuredDNA synthesis in
wild-type, p47phox/, and CD44/ cells treated with LMW-
HA. LMW-HA increased DNA synthesis in wild-type VSMC,
although the increase was not statistically significant (Fig. 4A).
Treatment with LMW-HA had no effect in CD44/ cells.
Thrombin significantly increased DNA synthesis in wild-type
and CD44 knock-out VSMC (p  0.01) but not in p47phox/
cells, consistent with our prior findings (28) (Fig. 4A). Throm-
bin pretreatment for 8 h prior to LMW-HA treatment
increased [3H]thymidine uptake inwild-type VSMCby 3.5-fold
comparedwith untreated cells (p 0.001) and by 2.2-fold com-
pared with LMW-HA treatment alone (p 0.01). LMW-HAor
thrombin pretreatment followed by LMW-HA had no signifi-
cant effect on DNA synthesis in p47phox/ or CD44/ cells.
Together, these results indicate that interaction of LMW-HA
with NADPH oxidase-dependent increased CD44 expression
plays an important role in VSMC proliferation.
FIGURE 3. Thrombin enhances LMW-HA-induced VSMC NADPH oxidase
activity by enhancing Rac1 activity. A, VSMC were treated with thrombin or
LMW-HA alone or pretreated with thrombin for 8 h and then treated with
LMW-HA. ROS generation was detected by measuring H2DCFDA fluores-
cence. Data are expressed in relative fluorescence units adjusted for protein
concentration (mean  S.E., n  4, *, p  0.05; **, p  0.001). B, growth-
arrested VSMC were treated with thrombin or LMW-HA or pretreated with
thrombin for 8 h and then treated with LMW-HA. Rac1 activation in protein
lysates containing equal amounts of protein was assessed using PAK-1 PBD
pull-down assay. Western analysis of total Rac1 was used as an internal con-
trol for measuring Rac1 activity in lysates containing equal amounts of pro-
tein. Densitometric analysis of Rac1 activity, represented as fold-change in
Rac1-GTP levels was calculated by first normalizing to total Rac1 levels in
individual samples and then relative to untreated wild-type control (mean 
S.E., n  3, *, p  0.01; **, p  0.001).
FIGURE 4. LMW-HA enhances thrombin-induced VSMC proliferation and
functional inhibition of CD44 attenuates thrombin-induced haptotactic
migration of VSMC toward HMW-HA. A, growth-arrested VSMC treated
with thrombin or LMW-HA or pretreated with thrombin for 8 h and then
treated with LMW-HA for 24 h. [3H]Thymidine uptake was measured during
the last 4 h of treatment. Data presented are mean  S.E. (n  3) and repre-
sentative of three separate experiments (*, p  0.01; **, p  0.001; NS, not
significant). B, haptotactic cell migration was measured using HMW-HA-
coated transwell filters. VSMC were treated with thrombin or pretreated with
thrombin for 8 h and then incubated with thrombin for 16 h. When antibody
was used, VSMC were incubated with anti-CD44 IgG or normal mouse IgG at
1:100 dilution for 30 min before being seeded on the filters. Data presented
are mean  S.E. (n  3) and representative of three separate experiments (*,
p  0.05; **, p  0.01).
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BecauseCD44 isoformswere known to enhancemigration of
melanoma cells onHA-coated surfaces (44, 45), we investigated
whether CD44 regulates thrombin-induced migration of
VSMC. In a haptotactic cell migration assay, a greater number
ofwild-type cellsmigrated towardHAas comparedwith bovine
serum albumin. Treatment with thrombin significantly
increased VSMC migration toward HA compared with
untreated control (p  0.05) (Fig. 4B). Thrombin pretreatment
for 8 h followed by thrombin treatment further enhanced
VSMC migration toward HA compared with thrombin treat-
ment alone (p  0.05). The migration of VSMC toward HA in
response to thrombin alone and thrombin pretreatment 
thrombin was significantly inhibited (p  0.05) by anti-CD44
mAb, whereas isotype-matched mouse IgG had no inhibitory
effect on the migration induced by thrombin pretreatment 
thrombin treatment. Together with the published data (4),
these CD44 functional inhibition studies indicate that throm-
bin-induced NADPH oxidase-dependent increased CD44
expression plays an important role inmigration towardHA and
LMW-HA-stimulated proliferation of VSMC.
NADPH Oxidase Regulates Expression of CD44 in the Aortas
andHA in the Atherosclerotic Lesions—Wepreviously reported
lower levels of immunoreactive CD44 in atherosclerotic lesions
in the aortas of apoE//p47phox/ mice compared with
apoE/ mice, correlating with the decreased lesion size in
apoE//p47phox/ animals (4). Here, we compared the sys-
temic expression of CD44 in protein lysates from aortas of
apoE/ and apoE//p47phox/ mice fed a Western diet.
The amount of CD44 in lysates from apoE/ aortas was 2.6-
fold higher than that from apoE//p47phox/ animals (p 
0.001) (Fig. 5A) as measured by ELISA.
Because expression of CD44 and its interaction with HA are
important determinants of the extent of atherosclerotic lesions
in mice (6), we performed immunohistochemical analysis of
HA expression in aortic sections of apoE/ and apoE//
p47phox/ mice fed aWestern diet. HA expression was signif-
icantly increased in apoE/ aortic sections compared with
those from apoE//p47phox/ mice (p 0.05) as detected by
immunostaining using HA-binding protein, followed by histo-
logical scoring (Fig. 5, B and C). Intense HA expression was
observed in the medial layer as confirmed by smooth muscle
-actin staining and inmacrophage-enriched, oil redOpositive
areas of plaques (Fig. 5B).
These in vivo findings suggest that mechanisms similar to
those observed in cultured VSMC for NADPH oxidase regula-
tion of CD44 and HA expressions are important in vivo.
Increased systemic expression of CD44 in apoE/ aortas also
indicates the role of NADPH oxidase in the induction of a pro-
inflammatory milieu in mice.
Plasma Soluble CD44 and HA Levels Are Down-regulated in
ApoE/ Mice Deficient in p47phox Subunit of NADPH Oxi-
dase—Shedding and release of soluble CD44 into the systemic
circulation is induced by various cytokines (46) and HA degra-
dation and turnover are regulated by ROS, processes character-
istic of an inflammatory response (18, 47). Furthermore,
increased plasma HA levels have been associated with diabetic
angiopathy and the susceptibility of diabetic patients to ather-
osclerosis (48, 49). Because the activation of NADPH oxidases
contributes to inflammation (50, 51), we investigated soluble
CD44 and HA levels in the plasma of apoE/ and apoE//
p47phox/ mice on a Western diet. Soluble CD44 levels
increased significantly in apoE/ mice as compared with
apoE//p47phox/ and wild-type mice (p  0.05) (Fig. 6A).
Similarly, plasma HA levels in apoE//p47phox/ mice were
significantly lower than those in apoE/ mice (p  0.01) (Fig.
6B). There was no significant difference in either plasma-solu-
ble CD44 or HA levels between wild-type and apoE//
p47phox/ mice. These data support our observation of
increased expression of CD44 and HA in the aortic wall of
apoE/ mice. Furthermore, they suggest that increased
NADPH oxidase-dependent degradation of HA and shedding
and release of soluble CD44 antigen into systemic circulation
FIGURE 5. CD44 expression is enhanced in aortas of apoE/ mice,
whereas HA expression was up-regulated in atherosclerotic lesions of
apoE/ mice as compared with apoE//p47phox/ mice. A, CD44
expression was measured in protein lysates from aortas of apoE/ and
apoE//p47phox/ mice using CD44 ELISA. Data expressed are mean  S.E.
of five mice in each group (*, p  0.001). B, representative aortic root sections
from apoE/ and apoE//p47phox/ mice were stained using biotinylated
HABP or oil red O. Localization of smooth muscle cell was shown by staining
for -SM actin. C, expression of HA in atherosclerotic lesions, determined by
immunohistochemistry scoring. Data are mean  S.E. (n  6, *, p  0.05).
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enhance the inflammatory process and promote atherosclero-
sis in proatherogenic milieu.
CD44 and HA-dependent Gene Expression is Regulated in
ApoE/ Mice in a NADPH Oxidase-dependent Manner—In-
teraction of CD44 with LMW-HA results in the induction of
chemokine gene expression in macrophages (36) and CD44
regulates vascular gene expression in atherosclerosis-prone
regions of the vasculature (52). Soluble HA was shown to
induce the expression of Il1, Tnf, and Igf1 in bone-marrow
derived macrophages (53) and Ccl2, Ccl4, and Ccl5 in alveolar
macrophages (36). We performed gene expression analysis of
aortas from mice fed a Western diet to determine whether
NADPHoxidase-dependent, increased expression ofCD44 and
HA will result in increased expression of the aforementioned
genes in apoE/ mice as compared with apoE//p47phox/
mice. Real time RT-PCR analysis showed significantly higher
levels of Ccl2, Ccl5, Tnf, and Igf1 expression in aortas of
apoE/ mice compared with the double knock-out mice (p 
0.05) (Table 1). Differences in the expression of Ccl4 and Il1
trended to higher levels but were not significant. These results
suggest that NADPH oxidase-dependent expression of CD44
and HA in the vascular wall and ROS-dependent HA degrada-
tion and release of LMW-HA leads to increased interaction of
CD44 and LMW-HA and induction of pro-inflammatory cyto-
kine expression in the vasculature and that this promotes
atherogenesis.
Pharmacologic Inhibition of Nox1/Nox4-based NADPH Oxi-
daseAttenuatesAtherosclerosis, ROSGeneration, Plasma8-Iso-
prostane Levels, and CD44 and HA Expression in Atheroscle-
rotic Lesions of ApoE/Mice—To confirm the role of NADPH
oxidase in the regulation of CD44 and HA expression
under pathophysiologic conditions, we tested the effect of
GKT136901 (Fig. 7A), a dual Nox1/Nox4 inhibitor, on athero-
sclerosis development in apoE/ mice and the presence of
CD44 andHA in atherosclerotic lesions. Nox4 regulates VSMC
migration (3) and its expression is significantly enhanced in
apoE/mice comparedwithwild-typemice (54). GKT136901
has aKi in the range of 150–250 nM for humanNox1 and Nox4
(Emax of 90–100% at 33M) in a cell-free system and is bioavail-
able following oral administration.4
GKT136901 treatment significantly decreased the aortic ath-
erosclerotic lesion area compared with vehicle treatment (p 
0.05) (Fig. 7B). There was no significant effect of GKT136901
on body weight, plasma total cholesterol, or triglyceride levels
(Table 2). GKT136901 did significantly inhibit aortic ROS pro-
duction as measured by the decrease in DHE fluorescence of
fresh-frozen cross-sections (p  0.05 versus vehicle) (Fig. 7C).
To quantify systemic oxidative stress, plasma 8-isoprostane lev-
els were determined using the Enzyme Immunoassay kit. A
modest but significant decrease (p 0.05) in plasma 8-isopros-
tane levels was observed in apoE/ mice treated with
GKT136901 compared with mice treated with the vehicle (Fig.
7D). Immunostaining of aortic cross-sections showed a signif-
icant decrease in CD44 and HA expression in atherosclerotic
lesions of apoE/ mice treated with GKT136901 compared
with those from mice treated with the vehicle (Fig. 7, E and F).
Furthermore, expression of monocyte/macrophage marker,
CD11b, was significantly decreased in atherosclerotic lesions in
mice treatedwithGKT136901 comparedwith the vehicle treat-
ment (Fig. 7, E and F). These results support our in vitro data
that NADPH oxidases regulate CD44 and HA expression and
together with other published reports (4) indicate that CD44-
and HA-dependent inflammatory cell recruitment and VSMC
activation promotes atherosclerosis.
Thrombin Regulates HASMC CD44 and HA Expression in
Nox1/Nox4-based NADPH Oxidase-dependent Manner—To
determine whether CD44 and HAS2 are regulated in a similar
manner in human vascular cells, we investigated thrombin-in-
duced CD44 and HAS2 expression in HASMC. Western blot
analysis revealed that thrombin regulates these proteins in a
time-dependent manner, with peak CD44 expression at 4 h and
4 C. Szyndralewiez and P. Page, unpublished data.
FIGURE 6. HA and soluble CD44 concentrations are increased in the
plasma of apoE/ as compared with wild-type and apoE//p47phox/
mice. A, soluble CD44 concentration in the plasma of wild-type, apoE/, and
apoE//p47phox/ mice was measured using a CD44 ELISA kit. Data
expressed are mean  S.E. of 12 mice in each group (*, p  0.05). B, HA
concentration in the plasma of wild-type, apoE/, and apoE//p47phox/
mice was measured using HA ELISA. Data expressed are mean  S.E. of 10
mice in each group (*, p  0.01).
TABLE 1
Analysis of gene expression in aortas of apoE/ versus apoE//
p47phox/ mice
Gene expression is based on real-time PCR analysis of RNA extracted from aortas
(n  7 for each genotype). Fold change calculated as expression in apoE/ relative











Ccl5 (regulated on activation,
normal T-cell expressed and
secreted)
NM_013653 4.90 0.027




Il1 (interleukin 1) NM_008361 3.37 0.120
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HAS2 at 8 h (Fig. 8A). As an approach to determine the impor-
tance of NADPH oxidase in CD44 and HAS2 expression in
HASMC, we treated cells with thrombin in the presence and
absence of GKT136901. Pretreatment of HASMC with 30 M
GKT136901 for 1 h prior to thrombin treatment significantly
inhibited intracellular ROS generation as measured by DCF fluo-
rescence (p 0.01) (Fig. 8B). GKT136901 also significantly inhib-
ited thrombin-inducedCd44mRNA levels at 2 and 4 h (p 0.001
andp0.05, respectively) andHas2mRNAlevels at 2h (p0.01)
(Fig. 8, C and D) without significantly affecting Nox1 or Nox4
expression (datanot shown).Consist-
ent with this, GKT136901 abrogated
any thrombin-induced increase in
CD44 and HAS2 proteins levels (Fig.
8, E and F). Together with mouse cell
culture and atherosclerosis model
results, these data underline the rele-
vance of ROS-sensitive regulation of
CD44, HAS2, and HA expression in
human atherosclerosis development.
DISCUSSION
The experiments reported here
demonstrate that: 1) NADPH oxi-
dase regulates thrombin induced
CD44 expression via activation of
AP-1; 2) increased synthesis and
degradation of HA in thrombin-
treated VSMC is regulated in
NADPH oxidase-dependent man-
ner; 3) LMW-HA enhances oxida-
tive stress by activating Rac1 and
subsequent induction of NADPH
oxidase activity; 4) interaction of
LMW-HA with NADPH oxidase-
dependent increased CD44 expres-
sion in thrombin-treated VSMC
plays a vital role in cell proliferation
and migration; 5) CD44- and HA-
dependent gene expression is signif-
icantly up-regulated in the aortas of
apoE/ mice compared with
apoE//p47phox/ mice; and 6)
GKT136901, a pharmacological
inhibitor of Nox1/Nox4-based
NADPH oxidases not only inhibits
oxidative stress, CD44 and HA
expression, and atherosclerosis in
apoE/ mice, but also attenuates
thrombin-induced ROS generation,
CD44 and HA expression in
HASMC. Together, these studies
indicate that CD44 and HA consti-
tute a Nox homologue-independent
NADPH oxidase-regulated redox-
sensitive signaling pathway active in
the pathogenesis of atherosclerosis.
We and others have reported that
CD44 expression is enhanced in response to arterial injury,
inflammation, and atherosclerosis (4, 6, 33), interrelated patho-
logic processes that are regulated in a redox-sensitive manner
(55). Our in vitro data that thrombin-stimulated CD44 expres-
sion is regulated by transcription factor AP-1 is consistent
with the redox-sensitive regulation of this adhesion mole-
cule and is in agreement with other reports (26, 33).
HA is synthesized inVSMCby threeHA synthases (56), how-
ever, HAS2 is almost certainly the major HA synthesizing
enzyme in VSMC based on two lines of evidence. First, when
FIGURE 7. Treatment with GKT136901, a pharmacologic inhibitor of Nox1/Nox4-based NADPH oxidases,
decreases atherosclerosis, ROS generation, plasma 8-isoprostane levels, and CD44 and HA expression
in atherosclerotic lesions in apoE/ mice. A, chemical structure of the selective Nox1/Nox4 inhibitor
GKT136901. B, aortas from apoE/ mice, fed a Western diet and treated with GKT136901 or vehicle, were fixed,
stained with oil red O (ORO), and photographed. Oil red O-stained area was quantified as percent of whole
aorta (mean  S.E., n  15, *, p  0.05 versus vehicle). C, fresh frozen sections of aortic root were stained with
DHE and fluorescence was detected using a confocal microscopy. Data are presented as integrated density
relative to area (mean  S.E., n  6, *, p  0.05). D, plasma 8-isoprostane levels were determined using the
Enzyme Immunoassay kit (mean  S.E., n  15, *, p  0.05). E, representative sections of aortic root stained for
CD44, CD11b, HA, and with oil red O. F, expression of CD44, HA, and CD11b as determined by immunohisto-
chemistry scoring (mean  S.E., n  6, *, p  0.05).
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Has2 is down-regulated using siRNA, VSMC proliferation is
inhibited (23). Second, VSMC-specific overexpression ofHAS2
enhances atherosclerosis in apoE/ mice (20). Our data indi-
cate that increasedHAS2 expression and activity in response to
thrombin treatment is dependent on NADPH oxidase activa-
tion. Furthermore, our data indicating that that NADPH oxi-
dase regulates Hyal3 expression in VSMC treated with throm-
bin is significant because increased HA during pathological
conditions is the sumof its synthesis
and catabolism. This is also an
interesting observation because
Hyal3/ mice do not exhibit any
HA accumulation (57) and cellular
overexpression of Hyal3 does not
impart intrinsic hyaluronidase
activity (58). In contrast, up-regula-
tion of Hyal3 was reported in chon-
drocytes treated with cytokines
(59). Although ROS can cleave HA
in laboratory tests (17) and HA lev-
els have been positively correlated
with other oxidative stress makers
in diabetic patients (47), evidence
for the direct action of ROS on HA
degradation in studies using cell
culture or cell-free extracts is
absent.
The increase in thrombin-in-
duced NADPH oxidase activity by
LMW-HA may be due to either
enhanced Rac1 activity (Fig. 3B) or
enhanced CD44 expression caused
by thrombin pretreatment, or both.
HA has been reported to induce
ROS production in a CD44-depen-
dent manner (43, 60) and NADPH
oxidase mediates the increase in
ROS production as down-regula-
tion of p47phox, p67phox, or Rac1
decreased ROS levels (43). Arterial
injury and atherosclerotic lesions
are characterized by enhanced
thrombin expression and activity
(40, 41) and increased ROS pro-
duction in the arteries of apoE/
versus apoE//p47phox/ mice
(29) may result from the interac-
tion of increased thrombin and
HA levels. NADPH oxidase activa-
tion increases HA synthesis and
LMW-HA enhances NADPH oxi-
dase activity suggesting a positive
feedback loop between HA and
NADPH oxidase activation.
Increased VSMC migration and
proliferation are important events
in the development of atherosclero-
sis and restenosis.Wild-type VSMC
FIGURE 8. GKT136901 inhibits thrombin-induced CD44 and HAS2 expression in HASMC. A, growth-
arrested HASMC were treated with thrombin for the indicated times. Expression of CD44 and HAS2 was
determined by Western blot analysis. B, HASMC were treated with thrombin or pretreated with various
concentrations of GKT136901 and then treated with thrombin. ROS generation was detected by mea-
suring H2DCFDA fluorescence. Data are expressed in relative fluorescence units adjusted for protein
concentration (mean  S.E., n  4, *, p  0.05; **, p  0.01). C, real time RT-PCR analysis of Cd44 RNA
expression in HASMC treated with thrombin alone or thrombin and GKT136901 for the indicated times.
Data represent fold-change in gene expression, normalized to 18 S RNA, and relative to untreated wild-
type control (mean  S.E., n  3, *, p  0.05; **, p  0.001). D, real time RT-PCR analysis of Has2 RNA
expression in cells treated with thrombin alone or thrombin and GKT136901 for the indicated times. Data
are expressed as fold-change in gene expression, normalized to 18 S RNA, and relative to untreated
wild-type control (mean  S.E., n  3, *, p  0.01). E, Western blot analysis of CD44 protein levels in HASMC
after an 8-h treatment with thrombin or GKT136901 alone or GKT136901 and thrombin together. Densi-
tometric analysis of CD44 protein levels, represented as fold-change, was calculated by first normalizing
to -actin levels in individual samples and then relative to untreated control (mean  S.E., n  3, *, p 
0.05). F, Western blot analysis of HAS2 protein levels in HASMC after an 8-h treatment with thrombin or
GKT136901 alone or GKT136901 and thrombin together. Densitometric analysis of HAS2 protein levels,
represented as fold-change, was calculated by first normalizing to -actin levels in individual samples and
then relative to untreated control (mean  S.E., n  3, *, p  0.05; **, p  0.01).
TABLE 2
Body weight, plasma cholesterol, and triglycerides levels in apoE/
mice fed a Western diet and treated with vehicle or
GKT136901 (mean  S.E., n  15)
Vehicle GKT136901
Weight, g 31.88  0.6176 32.05  0.4134
Cholesterol, mg/dL 570.5  67.39 603.0  73.58
Triglycerides, mg/dL 37.20  2.690 34.71  3.200
NADPH Oxidases Regulate CD44 and Hyaluronic Acid Expression
AUGUST 20, 2010 • VOLUME 285 • NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26555
proliferate more rapidly than p47phox/ VSMC in the pres-
ence of thrombin and LMW-HA, indicating that NADPH oxi-
dase activation and subsequent synthesis of CD44 are major
contributors of VSMC mitogenesis likely in vivo under patho-
physiological conditions. The importance of NADPH oxidase-
dependent CD44 expression in atherogenesis is supported by
our finding that thrombin-induced haptotactic migration of
VSMC is significantly decreased in the presence of monoclonal
anti-CD44 antibody.
The increase in CD44 expression observed in the current
investigation in the aortas of apoE/ mice (compared with
those in apoE//p47phox/ mice) together with the observa-
tion of Cuff et al. (6) that CD44//apoE/ mice develop sig-
nificantly decreased atherosclerosis (again compared with
apoE/ littermates) indicates that NADPH oxidases and
CD44 play a critical role in atherogenesis. The increase in
plasma sCD44 levels in apoE/mice comparedwithwild-type
and apoE//p47phox/ mice further indicates that activation
of NADPH oxidase in proatherogenicmilieu releases sCD44 by
proteolytic cleavage of membrane-anchored CD44. This may
well be from the stimulation of matrix metalloproteinases (61,
62). Our in vivo data showing increased HA expression in
medial VSMC of atherosclerotic lesions in apoE/ mice com-
pared with apoE//p47phox/ mice supports our cell culture
data of decreased HA levels in p47phox/ VSMC compared
with wild-type in response to thrombin treatment. These find-
ings are consistent with the observation of Chai et al. (20) that
overexpression of HA in aortic VSMC of apoE/ mice
increases atherosclerosis. Interestingly, apoE/ mice had
higher plasma HA levels than wild-type and apoE//
p47phox/ mice consistent with increased HA degradation
under proatherogenic conditions.
In addition to their role in VSMC proliferation and migra-
tion, CD44 andHAparticipate inmany processes that promote
atherogenesis. For example, CD44 contributes to the initial
rolling interaction between lymphocytes and endothelium and
once within the subendothelial space, CD44 mediates interac-
tions between leukocytes, VSMC, and parenchymal cells (19).
In this context it is noteworthy that pharmacologic inhibition of
Nox1/Nox4-based NADPH oxidase in apoE/ mice not only
attenuated ROS generation in the aortic wall and plasma 8-iso-
prostane levels but also decreased atherosclerotic burden,
CD44 and HA levels in the aortic wall andmacrophage recruit-
ment into these lesions (Fig. 7). To our knowledge, this is the
first study to show that a specific inhibitor of Nox1/Nox4 activ-
ity significantly decrease atherosclerosis in apoE/ mice. This
inhibitor may have therapeutic potential as it inhibited CD44
and HA expression and oxidative stress in HASMC. Increased
HA levels in medial VSMC were correlated with increased
mechanical stiffness and strength of the aortas, which is linked
to endothelial dysfunction and atherogenesis (20, 63). Because
HA interacts with lipoproteins through hydrophobic interac-
tions (64), increased HA might promote atherogenesis by
retaining lipoproteins in the arterial wall.
Finally, our analysis of knownHA-regulated genes (36, 53) in
the aortas of apoE/ and apoE//p47phox/ mice demon-
strated a NADPH oxidase-dependent regulation of Ccl2
(Mcp1),Ccl5 (RANTES),Tnf, and Igf1.MCP-1 plays an impor-
tant role in the recruitment of monocytes/macrophages to vas-
cular lesions. Localized overexpression of MCP-1 in the vessel
wall, in the backdrop of hypercholesterolemia, induces early
atherosclerotic lesions in rabbits (65) and increased expression
of serum MCP-1 was observed in hypertensive patients with
diffuse atherosclerosis as well (66). In concurrence with our
results, Bae et al. (67) have recently reported that RANTES is
regulated in a NADPH oxidase-dependent manner. Further-
more, a transient increase in RANTES levels was reported in
patients experiencing unstable angina pectoris (68). TNF-
plays a key role in the inflammatory cascade associated with
atherosclerosis (69) and several studies support the association
of increased TNF- levels with increased risk of myocardial
infarction (70, 71). The role of IGF-1 in atherogenesis is con-
troversial. Several studies suggest that IGF-1 accelerates
atherogenesis (72, 73), whereas another study has reported an
association of low serum IGF-1 levels with increased risk for
ischemic heart disease (74). Our data indicating pharmacologic
inhibition of Nox1/Nox4-based NADPH oxidase markedly
decreases CD44 and HA expression in the vascular wall vali-
dates our hypothesis that NADPH oxidase activation promotes
atherosclerosis via CD44- and HA-dependent processes.
In summary, our data provide insight into the molecular
mechanisms by which NADPH oxidase activation promotes
atherosclerotic lesion formation. NADPH oxidases mediate
agonist-induced HA synthesis by regulating both HA synthetic
and degradation enzymes and a positive feedback loop between
HA and NADPH oxidase increases oxidative stress and
enhances atherosclerosis. Interaction between increased CD44
and HA levels resulting from NADPH oxidase activation in
hyperlipidemic background induces chemokine, cytokine, and
growth factor production, which promote atherosclerosis. Spe-
cific inhibitors of NADPH oxidase function may provide an
effective therapy for treating atherosclerosis not just by
decreasing oxidative burden but also by attenuating the molec-
ular pathways that promote atherosclerosis.
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